Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year. ・Moderna was in focus after updated cancer vaccine data, while Novavax drew ...

--- ...

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Novavax, the Covid-19 vaccine maker, has licensed the rights for a vaccine-enhancing component to Pfizer. Pfizer agreed to pay $30 million upfront, and could pay up to $500 million more if development ...

Novavax (NVAX) stock jumps as the company announces a licensing deal with Pfizer (PFE) for its Matrix-M adjuvant. Read more here.

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company announced it entered into a license agreement with Pfizer for its Matrix-M ...

GoodRx reports on tracking prescription fills for flu and COVID-19 treatments, revealing seasonal trends and insurance ...

Sweeping changes to U.S. vaccine policy under Health Secretary Robert F. Kennedy Jr. are creating uncertainty across the pharmaceutical sector, dampening investor confidence and raising concerns among ...